Growth Hormone Releasing Peptide 6 · 10 mg / vial- ·3 mL bacteriostatic water
- ·10 × 1 mL insulin syringes
- ·Alcohol swabs
GHRP-6 10 mg
Non-selective ghrelin-receptor agonist — hexapeptide.
GHRP-6 is one of the first-generation growth-hormone-releasing peptides. Broader activity than ipamorelin — also elicits hunger response via ghrelin-receptor central effects.
What the peptide is.
GHRP-6 was one of the original GH-releasing hexapeptides, developed in the 1980s. As a non-selective ghrelin-receptor agonist, it elicits broader physiological effects than the later selective agonist ipamorelin, including measurable increases in appetite signalling.
Non-selective ghrelin-receptor (GHSR-1a) agonism — pulsatile GH release plus orexigenic signalling.
Reconstitution, storage, and handling.
Lab-technical guidance for the researcher handling the material. Not therapeutic dosing, not administration guidance — those are not within the scope of this supply.
- Recommended solvent
- Bacteriostatic water for injection (0.9% benzyl alcohol) — included with kit
- Typical volume
- 1 – 2 mL
- Inject diluent slowly down the side of the vial onto the cake.
- Swirl gently — do not shake.
- Solution should be clear and colourless. Discard if not.
- Lyophilised
- −20 °C, desiccated, protected from light. Stable at 15–25 °C for up to 30 days in transit.
- Reconstituted
- 2–8 °C, original vial, consumed within 4 weeks.
- Shelf life · sealed
- 24 months from date of manufacture when stored lyophilised at −20 °C.
- Shelf life · reconstituted
- Up to 4 weeks refrigerated.
- ▸Standard peptide handling.
This lot, documented.
Every shipment is accompanied by a signed four-page analytical report including the HPLC chromatogram, ESI-MS spectrum, purity calculation, and sample handling chain-of-custody.
The report you will receive is specific to the lot dispatched to you. The display below is a current representative example.
04:22:11▸lot 26-04-A received ┈ 5.00 g04:22:40▸weight check ┈ PASS ±0.4 mg04:23:12▸sample → janoshik ┈ 50 mg04:23:12▸tracking #jnk-921833405:18:03▸HPLC result ┈ 99.24 %05:18:04▸MS obs 4729.42 Da ┈ PASS05:18:05▸coa.pdf signed ┈ attached05:18:06▸lot approved ┈ LIVE
REPORT ID JA-26-04-012
SUBJECT GHRP-6 10 mg
DESIGNATION Growth Hormone Releasing Peptide 6
LOT 26-04-A
METHOD RP-HPLC, ESI-MS
COLUMN C18, 250 x 4.6 mm, 5 um
MOBILE PHASE A: 0.1% TFA in H2O
B: 0.1% TFA in ACN
GRADIENT 5 -> 65% B over 20 min
FLOW RATE 1.0 mL/min
DETECTION UV 214 nm
INJECTION 20 uL @ 0.5 mg/mL
---
PURITY (A%) 99.00
MASS EXP. 872.99 Da
MASS OBS. 873.01 Da
---
CONCLUSION Identity CONFIRMED · Purity PASS
SIGNED BY J. Novak, MSc · Janoshik Analytical SVK
DATE 2026-04-11Research references for GHRP-6 10 mg.
1 peer-reviewed publications. Links resolve to PubMed. DOIs are provided where available.
- [01]Bowers CY, Momany FA, Reynolds GA, Hong A
On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone
Endocrinology · 1984
- Q.Why choose GHRP-6 over ipamorelin?
- A.Different research profiles. Ipamorelin is cleaner (no cortisol/prolactin effects). GHRP-6 is broader and elicits orexigenic effects that may be desired or undesired in a research protocol.
This peptide is supplied by Omega Grade for in vitro laboratory research use. It is not a drug, food, cosmetic, or dietary supplement. It is not approved by the FDA, EMA, MHRA, PMDA, or any other regulatory authority for any therapeutic indication.
No claim of therapeutic benefit is made or implied. The material is not intended for human or veterinary consumption, administration, or any form of self-experimentation. By purchasing, you acknowledge the researcher terms and accept full responsibility for local import compliance and all handling.
Often considered alongside.
Ipamorelin 10 mg
Selective growth-hormone secretagogue — pentapeptide.
- Form
- Lyophilised kit
- Dose
- 10 mg / vial
- Purity
- ≥ 99.0%
CJC-1295 with DAC 5 mg
Long-acting GHRH analogue with Drug Affinity Complex.
- Form
- Lyophilised kit
- Dose
- 5 mg / vial
- Purity
- ≥ 99.0%